Jonathan R. Goodman

Jonathan R. Goodman (board member) discloses dealings in POINT Biopharma Global Inc. to SEC (Form 4). We count 4 filings; the first trade dates from 30 June 2021 and the latest from 26 December 2023.

Purchases make up the whole of the open-market record (1 purchase, €37k). A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 2 share grants.

The latest filing, published on 27 December 2023, reports a transaction in POINT Biopharma Global Inc. The most recent open-market purchase was published on 21 November 2022, 1,427 days ago. The median gap between a trade and its publication by SEC (Form 4) is 3 days. The legal deadline for a Form 4 is two business days after the transaction. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.